quizartinib — CareFirst (Caremark)
Acute Myeloid Leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive
Initial criteria
- Diagnosis of acute myeloid leukemia that is FLT3 internal tandem duplication (ITD)-positive confirmed by an FDA-approved test
- Used in any of the following settings: induction therapy or re-induction in combination with cytarabine and daunorubicin or idarubicin; consolidation therapy in combination with cytarabine; maintenance therapy as a single agent
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on current regimen
Approval duration
12 months (for up to 36 months maintenance therapy)